Low expression of PD-1 and/ or decreased frequency of CD8+ PD-1+ T cells are biomarkers for resistance to PD-1 immune checkpoint blockade (ICB) therapy in cancer patients (48). This evidence concerns the gene PDCD1 and cancer.